Maternal anti-Ro autoantibodies (Anti-Ro)

Maternal anti-Ro autoantibodies are pathogenic IgG molecules that cross the placenta and target fetal tissues, primarily the cardiac conduction system. These antibodies are directed against the Ro52 (TRIM21) and Ro60 (TROVE2) ribonucleoprotein complexes (StatPearls, NBK526060). In the fetus, the binding of these antibodies to cardiac myocytes leads to an inflammatory response, calcium channel interference, and eventual fibrosis of the atrioventricular node, resulting in permanent congenital heart block (Journal of Autoimmunity, 2014). They are also the primary drivers of neonatal lupus erythematosus, which manifests as cutaneous lesions and systemic involvement. Therapeutic management focuses on reducing the risk of fetal injury through the administration of hydroxychloroquine, which has been shown to significantly decrease the recurrence of heart block in high-risk pregnancies (PubMed, 32691540). Other interventions include the use of intravenous immunoglobulin (IVIG) to neutralize circulating antibodies and fluorinated corticosteroids to mitigate active fetal myocarditis.

Other names

Anti-SSA antibodiesAnti-Sjögren's-syndrome-related antigen A antibodiesAnti-Ro60 antibodiesAnti-Ro52 antibodiesAnti-TROVE2 antibodiesAnti-TRIM21 antibodies

Reduction of autoantibody production, competitive inhibition of placental antibody transport, and suppression of antibody-mediated inflammatory damage in fetal cardiac tissue.